THINK TANK BULLISH ON BIOTECHS
Monday October 23, 7:19 am Eastern Time
Press Release
New Biotech Report Highlights Record Investments, Forecasts, and Noteworthy Opportunities
SUNNYVALE, Calif.--(BW HealthWire)--Oct. 23, 2000--A new report from MRG, Inc. provides a crucial composite of active biotechnology companies, a sector now enjoying major advances in capital markets. U.S. Microarray/DNA Chip Industry: Current Status and Future Outlook: 2000-2010 profiles the multinational biotechnology corporate and university labs involved and the respective technologies and developments of each major player.
U.S. Microarray/DNA Chip Industry details how the biotech industry is gearing up for an entirely new era of DNA and biomedical breakthroughs. Many of these will bring extraordinary growth to certain industry segments, such as patient testing, pharmaceutical target screening, and disease research. Technologies analyzed include Spotting devices, On-Chip (in-situ) Synthesis, proteomics, Scanning/Detection, and ``Lab-on-a-Chip'' devices.
Growing from work on the Human Genome Project, biotech will have a phenomenal impact on the $1 trillion U.S. health care industry. Many firms are already seeing larger gains, and venture capitalists are now pumping record amounts of capital into the sector.
Details on certain DNA and electronic technologies pinpoint the promising opportunities to be found. For example, a section on strategic alliances lists key players from electronics and biotech sectors. Five case studies identify how research labs integrate these technologies for product development. The report also profiles individual companies participating in this growing field, and shows how science and electronics are intrinsically advancing medical research.
Analyst and writer, Dr. Elaine Mansfield, outlines recent industry changes. ``Many silicon and biotech innovators are targeting entirely new markets. Their vision and influx of capital created the biotechnology boom in Silicon Valley. The marriage of chip technology and knowledge from the Human Genome Project gave the industry a substantial opportunity to leverage its knowledge base and attack entirely new medical challenges,'' Mansfield concluded.
U.S. Microarray/DNA Chip Industry: Current Status and Future Outlook: 2000-2010 is a joint development of MRG, Inc. and Fuji-Keizai USA. It is available in English or Japanese for US$1,495.00 each. To order or request information, contact MRG at 408/524-9769 or info@mrgco.com.
About the Publishers
Founded in 1990, MRG has headquarters in Sunnyvale, California. MRG publishes market analyses of new technologies, and provides market intelligence and strategy consulting for client companies. Fuji-Keizai USA has offices in New York and Tokyo, and publishes business reports in English and Japanese. |
